# A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

> **NCT05869955** · PHASE1 · RECRUITING · sponsor: **Juno Therapeutics, Inc., a Bristol-Myers Squibb Company** · enrollment: 270 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Idiopathic Inflammatory Myopathy
- Systemic Sclerosis
- Rheumatoid Arthritis

## Interventions

- **DRUG:** CC-97540
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05869955
- **Lead sponsor:** Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-13
- **Primary completion:** 2028-08-29
- **Final completion:** 2028-08-29
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05869955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05869955, "A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05869955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*